Unlicensed Botox and filler injectors in Barbados: what the evidence warns

What Barbadian dentists reported

In April 2025, the Barbados Dental Association asked police to act against unlicensed providers. Its president, Dr Vidya Armogan, told Barbados Today that the problem went beyond teeth: "there are people doing botox fillers and mole removals"¹. "These are things that can go wrong quickly, and it's not fair to the Barbadian public", Dr Armogan said¹. The association described "illegal dental and cosmetic procedures performed by unlicensed individuals" and said "many of these illegal providers advertise their services on social media platforms like Instagram and Facebook"¹. According to the report, most unauthorised practitioners come from Jamaica, the United States and Trinidad, some local hair and nail technicians are being trained to perform procedures, and the law sets penalties "including fines up to $2 000 and six months in prison for violators"¹.

The concern fits a wider debate in Barbados. During the June 2026 debate on the new medicines law, minister Marsha Caddle warned that some products sold locally "were banned in many other jurisdictions" and called unverified health claims "a gap in the legislation and the regulatory regime that must be filled"³.

Botulinum toxin: what goes wrong outside licensed care

Botulinum toxin type A is a protein, among the most potent toxins known, used in small, measured doses. When the product or the injector is not what it claims to be, the result can be iatrogenic botulism. The largest series so far comes from a single centre: over ten years, it identified 161 cases of cosmetic iatrogenic botulism; 80 (49.69%) were admitted to hospital, and "most patients received botulinum toxin (BoNT) injections of unknown origin from unlicensed practitioners in nonmedical settings"⁷. Severe and moderate cases made up up to 60%, and hospitalised patients stayed a mean of 11.64 days⁷. The authors called it "the largest reported outbreak of illicit CIB worldwide" and urged "stringent surveillance of BoNT distribution"⁷.

The United States saw the same pattern in 2024. In April, the FDA warned that "unsafe counterfeit versions of Botox (botulinum toxin) have been found in multiple states", injected by licensed and unlicensed people, including in non-medical settings, and listed signs of a fake: lot number C3709C3, an active ingredient written as "Botulinum Toxin Type A" instead of onabotulinumtoxinA, a 150-unit strength the manufacturer does not make, and non-English text on the carton⁵. A CDC report in MMWR described seven women aged 26 to 55, four treated in Tennessee (one a Kentucky resident) and three in New York City, who fell ill after injections given in homes or, in one case, a cosmetic spa, by injectors who were unlicensed or suspected to be; four were admitted to hospital and two needed intensive care⁶. Case reports describe the clinical picture: a patient described by Miami physicians, injected at home by an unlicensed aesthetician, needed botulism antitoxin for bulbar paralysis and breathing difficulty⁹, and a 53-year-old woman with systemic botulism after cosmetic injections needed antitoxin and a feeding tube¹⁰.

Counterfeit toxin is not only a cosmetic problem. In Egypt in 2017, nine patients developed botulism after injections of a highly concentrated, unlicensed imported preparation sold as Neuroxin, given mainly for cerebral palsy; full recovery took 6 to 12 weeks and the product was withdrawn⁸. A 2024 review in Clinics in Dermatology confirms that "counterfeit or mishandled BoNTA has been associated with botulism", alongside rarer complications such as nontuberculous mycobacterial infections and vascular occlusion¹¹.

Fillers: the risk to sight

Dermal fillers carry a different danger: injection into a blood vessel. A 2015 review of the world literature found 98 cases of vision changes after filler injection, most often after treatment of the glabella and nose; most cases of vision loss did not recover¹². A 2019 update added 48 cases between 2015 and 2018, 81.3% caused by hyaluronic acid filler; only 20.8% recovered vision fully, and "there were no treatments that were shown to be consistently successful"¹³. The authors concluded that injectors need "a thorough knowledge of this complication including prevention and management strategies"¹³.

What the Barbados Medical Products Act changes

The Barbados Medical Products Act, 2026 (Act 2026-12), assented to on 18 June 2026 and in force on a date set by Proclamation, does not regulate who may perform an aesthetic procedure, but it does govern the products²:

• Import. "No person shall import a drug into Barbados" without a licence from the Authority, from a manufacturer the Authority has approved (section 37)².
• Registration. No one may import, sell or "otherwise place on the market" a medical product unless it is registered and granted marketing authorisation, with a $5,000 administrative penalty (section 43)².
• Advertising. Advertising a medical product needs the Authority's approval, and advertising for "off-label or non-evidence-based use" is prohibited (sections 48–49)².
• Falsified products. A "falsified medical product" is one whose "identity, composition or source" is false or misrepresented (section 2); the Authority can sample products and order recalls (sections 52–53)².
• Reporting. A National Pharmacovigilance Programme will collect reports of adverse reactions (section 51)².

The Authority is being set up with support from the Pan American Health Organization (PAHO), with a target of WHO Global Benchmarking Tool Maturity Level 3 by 2029⁴. Who may inject is still a matter for the professional registration laws, which is why the Dental Association took its complaint to the police¹.

Points for physicians in Barbados

Based on these sources, clinicians seeing a patient with ptosis, double vision, difficulty swallowing or limb weakness should ask about recent cosmetic injections, including those given at home or at parties⁶⁹¹⁰. Visual symptoms or skin blanching after a filler are an emergency¹²¹³. Products with the warning signs listed by the FDA can be reported⁵, and once the Act is in force, suspected falsified products and reactions go to the Authority's pharmacovigilance programme².